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Bone destruction is a major complication of advanced malignant
disease. It causes bone pain, pathological fracture and hypercal-
caemia. Tumour-associated osteolysis and hypercalcaemia is seen
in association with haematological malignancies (e.g. myeloma,
lymphoma) and solid tumours, mainly carcinomas, where it may
occur both in the presence (e.g. cancer of the lung, breast, thyroid,
kidney, etc.) and absence (e.g. cancer of the lung, breast, head and
neck, kidney, ovary, etc.) of bone metastases (Mundy, 1991;
Dodwell, 1992). Bone is one of the commonest sites of metastasis
in breast cancer and hypercalcaemia is seen in about one half of
patients with clinical evidence of breast carcinoma. 
The cellular and molecular mechanisms that account for the
bone destruction and consequent hypercalcaemia which occurs in
patients with advanced malignant disease are poorly understood.
Osteoclasts, multinucleated cells which form part of the mononu-
clear phagocyte system (Athanasou, 1996), effect the bone resorp-
tion in patients with skeletal metastasis (Galasko, 1976; Taube 
et al, 1994). Osteoclasts are formed by fusion of circulating mononu-
clear precursors cells of haematopoietic origin. In vitro studies
have defined the ontogeny of the osteoclast and characterized the
essential cellular and humoral factors which are required for 
osteoclast differentiation from haematopoietic and circulating
osteoclast precursors. In both mouse and man, mononuclear osteo-
clast precursors circulate in the monocyte fraction and express 
a monocyte/macrophage rather than an osteoclast phenotype
(Udagawa et al, 1990; Quinn et al, 1996; Fujikawa et al, 1996).
Osteoclast differentiation from these circulating precursors re-
quires the presence of M-CSF and involves a receptor–ligand
interaction with osteoblasts which express a membrane-bound
osteoclast differentiation factor (ODF) (Nakagawa et al, 1998;
Yasuda et al, 1998). 
In previous studies we have shown that tumour-associated
macrophages (TAMs) isolated from primary human breast and
mouse mammary carcinomas, when cocultured with bone-derived
stromal cells in the presence of 1,25(OH)2D3 and M-CSF, are able
to differentiate into multinucleated osteoclasts that are capable of
extensive lacunar bone resorption (Quinn et al, 1994, 1998). This
finding is of interest with regard to the pathogenesis of tumour
osteolysis in breast cancer as, in addition to an increase in osteo-
clast number, a prominent macrophage infiltrate is commonly
found in metastatic breast carcinomas (Bugelski et al, 1987; 
Van Ravenswaay Claasen et al, 1992). Moreover, osteoclasts are
required for growth of breast cancer metastases in bone and
tumour osteolysis involves recruitment of osteoclast precursors
and activation of mature osteoclasts (Clohisy et al, 1996a, 1996b;
Clohisy and Ramnaraine, 1998). 
In this study, our aim has been to analyse the cellular mecha-
nisms of bone resorption in breast cancer. As TAMs in meta-
stases of breast cancer are derived from circulating monocytes
(Mantovani et al, 1992), we have sought to determine whether the
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number of circulating osteoclast precursors in the monocyte 
fraction is increased in patients with metastatic breast cancer
compared to patients with primary breast cancer alone and normal
age-matched females. We have similarly assessed the number of
osteoclast precursors in 2 cases of hypercalcaemia of malignancy
associated with breast cancer, one with skeletal metastases, the
other a case of (non-metastatic) humoral hypercalcaemia of malig-
nancy. We have also analysed the sensitivity of circulating osteo-
clast precursors in breast cancer patients to various humoral factors
required for osteoclastogenesis and determined whether breast
carcinoma cells produce soluble factors that promote macrophage–
osteoclast differentiation and malignant bone resorption. 
MATERIALS AND METHODS 
Media and sera 
Incubations were performed in alpha minimal essential medium
(MEM) (Gibco, Paisley, UK) supplemented with glutamine (2 mM),
benzyl penicillin (100 IU ml–1), streptomycin (100 mg ml–1), and
10% fetal calf serum (FCS) (TechGen, London, UK). MEM alone or
Hank’s balanced salt solution (HBSS) (Gibco, Paisley, UK) were
used for cell isolation. Cloned, hormone responsive, calcitonin
receptor-negative, osteoblast-like UMR106 cells (derived from a rat
osteosarcoma-derived cell line) and human parathyroid hormone-
related protein (PTHrP) were obtained from Prof TJ Martin,
Melbourne, Australia (Partridge et al, 1981). 1,25(OH)2D3 (Solvay
Duphar, NL) and dexamethasone (Sigma, UK) were dissolved in
absolute alcohol and stored at –20˚C. Human M-CSF and human
interleukin-6 (IL-6) (R&D Systems Europe, Abingdon, UK) were
dissolved in MEM/FCS and stored at –20˚C. 
Preparation of monocyte-UMR cocultures on dentine
slices and coverslips 
Peripheral blood was drawn from 22 patients with breast cancer (±
evidence of metastatic disease) (Table 1) and 20 age-matched
normal female volunteers. One patient had hypercalcaemia
without evidence of metastases. At the time blood was taken,
patients were not under chemotherapy or hormone treatment. All
patients had normal white cell counts (4–11 ´ 109 l–1), and the
monocyte fraction was within the normal range (0.2–0.8 ´ 109 l–1).
The blood was collected and diluted 1:1 in MEM, layered over
Ficoll-Hypaque (Pharmacia, UK), then centrifuged (693 g),
washed and resuspended in MEM/FCS. The number of cells in the
resulting suspension of peripheral blood mononuclear cells
(PBMCs) was counted in a haemocytometer after lysis of red cells
using a 5% (v/v) acetic acid solution. 
Dentine slices (4 mm diameter), prepared as previously de-
scribed (Quinn et al, 1994), and glass coverslips (6 mm diameter)
were placed in 96-well tissue culture plates. 2 ´ 104 UMR106
osteoblast-like cells were added to each well and then cultured on
the dentine slices and coverslips for 24 hours in MEM/FCS. The
cell suspension of PBMCs (1 ´ 105 cells well–1) was then settled on
these coverslips and dentine slices for 2 h. The coverslips and
dentine slices were then removed from the wells, washed vigor-
ously in MEM/FCS to remove non-adherent cells, then placed in 24
well tissue culture plates containing 1 ml MEM/FCS. The cell
cultures were incubated in the presence of 1,25(OH)2D3 (10–7 M),
dexamethasone (10–8 M) and M-CSF (25 ng ml–1) for up to 21 days. 
Histochemical and immunohistochemical
characterization of cultured cells 
Histochemical staining for tartrate-resistant acid phosphatase
(TRAP) was carried out using a commercially available kit
(Sigma, UK). Cell preparations were fixed in citrate/acetone solu-
tion and stained for acid phosphatase, using naphthol AS-BI phos-
phate as a substrate, in the presence of 1.0 M tartrate; the product
was reacted with fast garnet GBC salt (Andersson et al, 1992). 
Cell preparations on coverslips were also stained immunohisto-
chemically by an indirect immunoperoxidase technique (Gatter et
al, 1984) with the monoclonal antibody 23C6 (a gift of Professor
MA Horton, London, UK): this is directed against CD51, the
vitronectin receptor (VNR), a highly osteoclast-associated antigen
(Horton et al, 1985). Cell preparations were similarly stained with
the monoclonal antibody GRS1, directed against CD14 (Schloss-
man et al, 1995), a macrophage-associated antigen which is known
not to be expressed by osteoclasts (Athanasou and Quinn, 1990). To
quantify the number of VNR multinucleated cells formed in cocul-
tures on coverslips, the number of these cells were counted in 4
fields of view (10 ´ objective) on coverslips and the mean taken.
Cells containing 2 or more nuclei were considered multinucleated. 
Functional evidence of osteoclast differentiation:
detection of lacunar resorption 
Functional evidence of osteoclast differentiation was determined
by a lacunar resorption assay system using cell culture on dentine
slices; the latter provides a smooth-surfaced mineralized substrate
for the assessment of lacunar resorption (Boyde et al, 1984). At the
end of the coculture period, dentine slices were placed in NH4OH
(1 M) for 30 minutes and cleaned by ultrasonication to remove
adherent cells. The slices were then washed with distilled water
and stained with 0.5% (v/v) toluidine blue for 3 minutes, then
washed again. The extent of lacunar resorption was quantified by
counting the number of resorption pits on the slice by light
microscopy. 
Table 1 Clinical details of breast cancer patients from whom peripheral
blood mononuclear cells were obtained 
Sex Age Bone metastases Hypercalcaemia 
Patient 1 F 50 – – 
Patient 2 F 61 – – 
Patient 3 F 46 + + 
Patient 4 F 61 – + 
Patient 5 F 68 – – 
Patient 6 F 52 – – 
Patient 7 F 49 + – 
Patient 8 F 74 + – 
Patient 9 F 60 – – 
Patient 10 F 45 – – 
Patient 11 F 71 – – 
Patient 12 F 64 – – 
Patient 13 F 81 + – 
Patient 14 F 76 + – 
Patient 15 F 69 + – 
Patient 16 F 78 + – 
Patient 17 F 57 + – 
Patient 18 F 77 + – 
Patient 19 F 64 + – 
Patient 20 F 62 – – 
Patient 21 F 62 + – 
Patient 22 F 72 – – Assessment of the number of circulating cells in breast
cancer patients and controls 
To determine the number of circulating osteoclast precursors in the
monocyte fraction of whole blood in breast cancer patients and
controls, serial dilutions of PBMCs (1 ´ 105–1 ´ 102 cells) were
added to each well and the cocultures maintained in the presence
of 1,25(OH)2D3, dexamethasone and M-CSF for up to 21 days.
Osteoclast formation in these cocultures was assessed by TRAP
and lacunar resorption. 
The effect of osteoclastogenic factors (M-CSF,
1,25(OH)2D3, IL-6 and PTHrP) on osteoclast formation in
breast cancer patients and normal controls 
In order to determine if osteoclast precursors in the peripheral blood
of breast cancer patients relative to normal controls, were more
sensitive to the effect on osteoclastogenesis of M-CSF and
1,25(OH)2D3, the extent of osteoclast formation and lacunar resorp-
tion was assessed in 21 day UMR 106-monocyte cocultures in the
presence of varying concentrations of human M-CSF (1–25 ng ml–1)
and 1,25(OH)2D3 (10–8–10–10 M). The addition of IL-6 (10–
100 ng ml–1) and human PTHrP (10–100 ng ml–1), factors which are
known to stimulate osteoclast formation and bone resorption in
malignancy (Mundy, 1991; Dodwell, 1992; Rosol and Capen,
1992) to monocyte-UMR-106 cocultures was similarly assessed in
terms of stimulation of osteoclast formation and lacunar resorption. 
The effect of breast carcinoma cells on osteoclast
formation and lacunar resorption 
Human breast carcinoma-derived cell lines MDA-MB 435 (Price
et al, 1990) and MCF-7 (Soule et al, 1973) were subcultured and
then grown for 72 h in MEM/FCS. The supernatant from these
cultures was decanted and centrifuged at 693 g for 7 min prior to
filtering in order to remove cellular material and to provide condi-
tioned medium for the subsequent experiments. The conditioned
medium was added separately to the monocyte-UMR106 cocul-
tures at final concentrations of 0.01 and 0.1% (v/v). Incubations on
glass coverslips were performed over 14 days and those on dentine
slices over 21 days. 
Statistical analysis 
Each series of experiments was repeated at least 3 times. The
results obtained from the experiments were expressed as the
percentages (mean ± SEM) of lacunar resorption in experimental
cultures to those in each control culture. Significant differences
were determined using Student’s t-test. 
RESULTS 
Histochemical, immunohistochemical and functional
characterization of isolated and cultured PBMCs from
breast cancer patients 
Adherent mononuclear cells isolated from the peripheral blood of
breast cancer patients and controls, which had been settled on
glass coverslips and cultured for 24 h, were characterized as
monocytes on the basis that they expressed CD14, a macrophage-
associated antigen which is known not to be expressed by 
osteoclasts (Athanasou and Quinn 1990), and were entirely nega-
tive for the osteoclast markers, TRAP and VNR (Horton et al,
1985). In addition, 24 h culture of PBMCs on dentine slices did
not show evidence of lacunar resorption. 
Osteoclast formation and lacunar resorption in
monocyte-UMR106 cocultures 
Monocytes from all cancer patients and controls, when cocultured
with UMR 106 cells, in the presence of 1,25(OH)2D3, dexametha-
sone and M-CSF, were capable of osteoclast differentiation as
shown by the formation of TRAP- and VNR-positive multinucle-
ated cells and lacunar resorption pit formation. After 14 days incu-
bation on glass coverslips, the cocultures contained numerous
TRAP (Figure 1) and VNR-positive mononuclear and multinucle-
ated cells. There was no obvious increase in the number of TRAP-
and VNR-positive multinucleated cells formed from monocytes
derived from controls and breast cancer patients. The mean
number (± SEM) of VNR-positive multinucleated cells formed
under these conditions was 5.88 (± 1.1) and 6.85 (± 2.40) for
controls and breast cancer patients respectively. In 21 day cocul-
tures there was extensive lacunar resorption pit formation on
80 NCA Hunt et al 
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Figure 1 Numerous tartrate-resistant acid phosphatase-positive
multinucleated osteoclasts in a 14 day coculture of UMR-106 osteoblast-like
cells and monocytes from breast cancer patients (´250 original
magnification) 
Figure 2 Extensive lacunar resorption pit formation on dentine slices after
21 days coculture of monocyte-derived osteoclasts and UMR-106 cells
(Toluidine blue staining. ´100 original magnification) dentine slices (Figure 2). Cocultures of PBMCs (1 ´ 105 cells per
well) and UMR 106 cells incubated for 21 days showed no increase
in lacunar resorption in control and breast cancer (± bone meta-
stases) patients (Figure 3). Neither the number of VNR-positive
multinucleated cells nor the extent of lacunar resorption pit forma-
tion was associated with the menopausal status of control or cancer
patients. 
Comparison of the number of circulating osteoclast
precursors in controls and breast cancer patients 
Serial dilution of the leucocyte suspension, both from breast
cancer patients and normal controls, added to dentine slices,
showed that lacunar resorption pits were formed when as few as
100 cells were added to each well. Cocultures of UMR 106 cells
with monocytes derived from all breast cancer patients, incubated
for 21 days with UMR 106 cells in the presence of 1,25(OH)2D3,
M-CSF, and dexamethasone, showed a small but not significant
increase in the number of resorption pits formed on dentine slices
compared with cell cultures from age-matched female controls
(Figure 4). 
Comparison of the effect of osteoclastogenic factors
on monocyte–osteoclast formation in controls and
breast cancer patients 
There was no difference in the sensitivity of monocytes derived
from breast cancer patients (± evidence of metastases) compared
to that of monocytes derived from age-matched controls to 
form osteoclasts in the presence of varying concentrations of
1,25(OH)2D3, M-CSF, IL-6 and PTHrP. In 21 day cocultures of
UMR106 cells and monocytes, derived from both breast cancer
patients (± evidence of metastases) and controls, incubated in the
presence of 10–8 M and 10–9 M 1,25(OH)2D3, (with 25 ng ml–1
M-CSF and 10–8 M dexamethasone), no statistically significant
difference was seen in the extent of lacunar resorption pit forma-
tion on dentine slices (Figure 5). In the presence of 10–10 M
1,25(OH)2D3, resorption pits were not formed in either breast
cancer (± metastases) or control patients. In the presence of 5 ng
ml–1 M-CSF, there was no evidence of pit formation in cocultures
of UMR 106 cells and monocytes derived from either breast
cancer or control patient. The lowest concentration of M-CSF at
which pit formation was seen in both breast cancer and control
patients was 10 ng ml–1. No evidence of TRAP expression or
lacunar resorption was seen when 1,25(OH)2 D3 was replaced with
IL-6 or PTHrP. Control and breast cancer patients also showed no
difference in resorption when PTHrP or IL-6 was added to the
monocyte-UMR 106 cocultures. 
The effect of conditioned medium from cultured breast
cancer cells on monocyte–osteoclast differentiation 
An increase in TRAP and VNR expression and lacunar resorption
was seen in cocultures of UMR106 cells and monocytes incubated in
the presence of conditioned medium from cultures of MCF-7 cells or
MDA-MB-435 cells compared to control monocyte-UMR106
Bone resorption in breast cancer 81
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Figure 3 Lacunar resorption pit formation in cocultures of monocyte-UMR
106 breast cancer patients and age-matched controls 
50
40
30
20
10
0
N
u
m
b
e
r
 
o
f
 
r
e
s
o
r
p
t
i
o
n
 
p
i
t
s
Control Control Control Breast
cancer 
Breast
cancer 
Breast
cancer 
1 ´ 104 cells 1 ´ 102 cells 1 ´ 103 cells
Figure 4 The effect on resorption pit formation of adding serial dilutions of
PBMCs derived from breast cancer patients and age-matched controls 
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Figure 5 Lacunar resorption pit formation of UMR 106-monocyte cocultures
in breast cancer patients compared to normal controls following the addition
of 10–8 M and 10–9 M 1,25(OH)2D3
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Figure 6 Dose-dependent increase in lacunar resorption pit formation
following the addition of the conditioned medium of cultured MDA-MB 435
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cocultures. The mean number (± SEM) of VNR-positive multinucle-
ated cells formed when conditioned medium from MCF-7 cells and
MDA-MB-435 cells was added compared to that of control mono-
cyte-UMR106 cocultures was 7.20 ± 1.29, 8.00 ± 3.31 and 4 ± 0.87
respectively. There was also a marked increase in the extent of
lacunar resorption in cocultures on dentine slices under these condi-
tions. The increase in osteoclast formation and resorption pit forma-
tion was more marked in cocultures treated with culture supernatant
derived from oestrogen receptor-positive MCF-7 cells than in those
treated with culture supernatant from oestrogen receptor-negative
MDA-MB-435 cells. The addition of culture supernatant from both
tumour cell types, however, was found to stimulate osteoclast forma-
tion and lacunar resorption in a dose-dependent manner (Figure 6). 
DISCUSSION 
Mature osteoclasts, which are the only cells capable of lacunar
bone resorption, develop from a marrow-derived population of
mononuclear precursor cells which circulate in the monocyte frac-
tion of peripheral blood. M-CSF is an essential humoral require-
ment for osteoclast formation and 1,25(OH)2D3 is known to
promote human osteoclast formation from marrow and circulating
precursors in vitro (Tanaka et al, 1993; Fujikawa et al, 1996).
Increased osteoclast formation is likely to play a central role in the
osteolysis associated with the hypercalcaemia of malignancy and
bone metastases in breast cancer. PTHrP production by tumour
cells produces hyperparathyroidism-like changes in bone with an
increase in osteoclast numbers and lacunar resorptive activity
(Mundy, 1991; Dodwell, 1992; Rosol and Capen, 1992). Osteo-
clasts are also numerous in the vicinity of enlarging breast cancer
metastases in bone (Galasko, 1976; Taube et al, 1994). 
In this study, we have shown that circulating osteoclast precur-
sors in breast cancer patients, including cases with skeletal metas-
tases and 2 cases of malignant hypercalcaemia, are not increased in
number compared to normal controls. We have also shown that
these precursors are not more sensitive to the effect of humoral
factors (1,25(OH)2D3, M-CSF, PTHrP and IL-6) which are known
to promote osteoclast formation and bone resorption. These results
suggest that the increase in osteoclast formation and bone resorp-
tion associated with metastatic bone lesions and the hypercal-
caemia of malignancy in breast cancer is not due to an increase in
the number of circulating mononuclear phagocyte osteoclast
precursors or the response of these cells to humoral factors which
promote osteoclastogenesis. The addition of conditioned medium
from cultured breast cancer cells, however, was found to promote
monocyte–osteoclast differentiation, indicating that carcinoma
cells in metastatic bone lesions may release soluble factor(s) which
promote malignant bone resorption. 
A role for increased osteoclast formation in malignant bone
resorption and the pathogenesis of the hypercalcaemia of malig-
nancy is indicated by recent studies which have shown that osteo-
clastogenesis inhibitory factor (osteoprotegerin), a novel secretory
factor which blocks the interaction between ODF (RANKL)-
expressing bone stromal cells and RANK-expressing osteoclast
precursors, induces hypocalcaemia in hypercalcaemic nude mice
carrying tumours which cause the hypercalcaemia of malignancy
(Akatsu et al, 1998). Although we were able to study only 2 cases
of hypercalcaemia of malignancy associated with breast cancer
(one of which also had metastatic lesions in bone), we did not find
that this condition was associated with an increase in the number
of circulating osteoclast precursors found in the monocyte fraction.
These precursors were also not more sensitive to the effect of
1,25(OH)2D3 which is essential for osteoclast formation in this in
vitro system. Increased osteoclast formation was also not seen
after the addition of IL-6 or PTHrP, factors which are known to be
released in the humoral hypercalcaemia of malignancy (Rosol and
Capen, 1992). The inability of 1,25(OH)2D3 to increase osteoclast
formation from circulating precursors may also be of relevance to
those cases of hypercalcaemia associated with haematological
malignancies in which there is an increase in serum 1,25(OH)2D3
(Suda et al, 1986; Mundy, 1991; Dodwell, 1992; Rosol and Capen,
1992). 
An increase in osteoclast numbers and activity is seen in the
vicinity of osteolytic bone metastases. A role for increased osteo-
clast formation in the osteolysis of breast cancer metastases has
been suggested by previous studies which have shown that TAMs
in primary human breast carcinomas are capable of differentiating
into functional bone resorbing osteoclasts when cultured with
osteoblast-like cells in the presence of 1,25(OH)2D3 and human 
M-CSF (Quinn et al, 1998). The results of the present study show
that the number of TRAP and VNR-positive cells formed from
cells of the monocyte fraction was not increased in breast cancer
patients relative to controls. This suggests that the number of
primed mononuclear phagocyte osteoclast precursors in the circu-
lation (and thus presumably in the monocyte-derived TAM popu-
lation), is not increased in breast cancer patients with bone
metastases relative to normal controls or breast cancer patients
who do not have metastatic disease. It is well-recognized that there
is some individual variation in the extent of lacunar resorption by
osteoclasts formed from circulating precursors (Fujikawa et al,
1996; Jevon et al, 2000; Shalhoub et al, 2000) and this was evident
in both the control and breast cancer patient populations studied;
this variation was not related to menopausal status and, given the
fact that the number of VNR-positive multinucleated cells formed 
was not significantly different between the 2 patient groups, most
likely reflects differences in the bone-resorbing activity of osteo-
clasts generated in vitro. Osteoclast precursor cells in the mono-
cyte fraction of breast cancer patients with bone metastases were
also not more sensitive to the effect of M-CSF and 1,25(OH)2D3,
factors which are required for osteoclast formation. In addition,
PTHrP and IL-6, humoral factors which are known both to be
produced by metastatic breast carcinoma cells and to play a role in
the increased osteoclast formation associated with the tumour
osteolysis (Mundy, 1991; Dodwell, 1992; Rosol and Capen, 1992),
did not stimulate osteoclastogenesis. 
In this study, we found that the conditioned medium derived
from cultures of breast cancer cells stimulated osteoclast formation
from circulating precursors. As these mononuclear phagocyte
precursors are part of the (monocyte-derived) TAM population of
metastatic tumours, these findings are of significance with regard
to the localized bone resorption that accompanies skeletal metas-
tasis. Our results are supported by the recent findings of Grano et
al (2000) who showed that an increased number of TRAP-positive
cells is formed in human bone marrow cultures to which the condi-
tioned medium of cultured breast cancer cells is added; the osteo-
clastic nature of the multinucleated cells formed in these human
marrow cultures, however, was not confirmed functionally (i.e. by
demonstration of lacunar resorption). Tumour cells are known to
secrete factors some of which (e.g. IL-3 and GM-CSF) have been
shown to promote osteoclast formation from monocyte precursors
(Fujikawa et al, 2001). Lee et al (1991) showed that cultures of a
cell line derived from a murine mammary carcinoma that inducedhypercalcaemia was associated with the release of an osteoclast
CSF. Other cultured breast cancer cell lines, known to produce
prostaglandins and leukaemia inhibitory factor, have also been
shown to promote osteoclastogenesis via a stromal cell-dependent
pathway (Akatsu et al, 1998, Ono et al, 1998). 
1,25(OH)2D3 and M-CSF receptors have been demonstrated on
breast cancer cells (Suda et al, 1986; Kacinsky 1998) and it is
possible that 1,25(OH)2D3 and M-CSF enhance osteoclast forma-
tion by an effect on tumour cells (possibly through ODF produc-
tion) as our results suggest that these factors do not appear to act
directly on osteoclast precursors. A role for ODF in breast cancer-
induced osteolysis is suggested by the observation that breast
cancer cells stimulate osteoblast production of ODF (Thomas et al,
1998); breast cancer cells are also known to express RANK, which
interacts with ODF, and to produce OPG, the soluble decoy
receptor for ODF. Taken together, these findings point to a role for
tumour cell-derived factors in controlling osteoclast formation
from mononuclear phagocyte precursors. 
Our data indicate that the increase in osteoclast formation which
occurs in both malignant hypercalcaemia and in metastatic bone
lesions in breast cancer is not due to a change in either the number
or nature of circulating osteoclast precursors, but is most likely a
function of the bone microenvironment. All the cellular and
humoral elements which are required for osteoclast differentiation
can be found in the microenvironment of a metastatic carcinoma 
in bone. Our results suggest that tumour cells directly influ-
ence monocyte/macrophage–osteoclast differentiation through the
release of soluble factors which promote osteoclastogenesis. This
leads to an increase in bone resorption and is likely to be one of the
means whereby increased osteoclast numbers and bone resorption
develop in skeletal metastasis. Further studies are needed to deter-
mine whether a similar mechanism underlies the malignant bone
resorption which is seen in the (non-metastatic) humoral hypercal-
caemia of malignancy. 
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